Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing human enzyme therapeutics to benefit people with rare metabolic diseases, today announced interim results from the ongoing Phase 1/2 clinical trial of pegtarviliase, a novel recombinant human enzyme engineered to reduce elevated levels of total homocysteine, for the treatment of Classical Homocystinuria. Following its review of the interim results, the company announced that it is exploring strategic alternatives with the goal of maximizing shareholder value.
https://finance.yahoo.com/news/aeglea-biotherapeutics-announces-interim-results-110000507.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.